NewBeauty Facebook Pinterest Instagram Youtube find a doctor Face Adult Acne Antioxidants Anti-Aging Celebrity Chronic Skin Conditions Eye Hydration Hyperpigmentation Makeup View All Eyebrows Eye Color Foundation Fragrance Lip Color Makeovers Male Skin Care Peels Pre-Event Prep Sensitive Skin Skin Care Skin Health Smile Sun Care Treatments Fillers Microneedling Post-Procedure Skin Care Neurotoxins Regenerative Aesthetics Skin Lifting Body Body Sculpting Breasts Butts Cellulite Hair Removal Hands + Nails Legs Pregnancy Find a Doctor Hair Bond Repair Celebrity Dry Hair Frizzy Hair Gray Hair Hair Color Hair Growth Hair Repair Scalp Health Styling + Tips Awards NB100 Awards 15th Annual Beauty Awards 2025 NewBeauty Readers’ Choice Awards Shopping Gift Guides Product Reviews NewBeauty Storefront Wellness Fitness GLP-1s Health Menopause About Us TESTTUBE Search for: Search HomeWellnessGLP-1s WHO Breaks New Ground With GLP-1 Obesity Guidelines It marks a new chapter for one of today’s most talked-about treatments. NewBeauty Editors Published: Dec 3, 2025 Getty Images Despite their origins as diabetes medications, much of the GLP-1 conversation now centers on weight loss. FDA-approved options such as Wegovy and Zepbound are marketed for weight management, and the growing off-label use of Ozempic has only intensified the trend. But now we have more clarity: As of Monday, December 1, the World Health Organization (WHO) released its first guidelines on the use of GLP-1 medications to address obesity—providing evidence-based recommendations on when these drugs are appropriate, how long they should be used and how they fit into comprehensive, long-term care. The guidelines lay out two main recommendations, backed by a few good practice notes to shape how obesity should be managed long-term. The first: Adults with obesity (BMI> 30 kg/m²) can use GLP-1 medications as long-term treatment, defined by WHO as continued use for 6 months or longer. The second recommendation says people on GLP-1s may…

Read the full article →